Browse All

Current Filters

CLEAR FILTER x

TITLE

ND0612 Infusion Dramatically Reduces OFF-time and Improves Quality of Life in Parkinson’s Disease: A Meta-analysis of Randomized Trials

Author:Lin, Shenney   Pitton Rissardo, Jamir   Elmandouh, Omar   Fornari Caprara, Ana Leticia   Walker, Ian M.   

Session Name:P8: Movement Disorders: Parkinson's Disease Emerging Therapeutics 2  

Topic:Movement Disorders  

Program Number:P8.009  

Author Institution:Cooper Medical School of Rowan University, NJ  Cooper University Hospital, Camden, NJ  Cooper University Hospital, NJ  

Phase One Study of BT-267: A Potent, Selective, Brain-penetrant, and Oral Small Molecule Inhibitor of LRRK2

Author:Dam, Tien   Dokukina, Kate   Remeeva, Eugenia   Kazey, Vasily   Karapetian, Ruben   Pushechnikov, Alexei   Mathias, Anita   Marvasty, Idean   Savchuk, Nikolay   Dukes, Iain   Hilt, Dana   

Session Name:P8: Movement Disorders: Parkinson's Disease Emerging Therapeutics 2  

Topic:Movement Disorders  

Program Number:P8.010  

Author Institution:Brenig Therapeutics, Dover, DE  Brenig Therapeutics, DE  Brenig Therapeutics, Lamoine, ME  

Clinical and Immunologic Safety Evaluation of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Parkinson’s Disease

Author:Onuigbo, Chiamaka   Saltarrelli, Jerome   Martinez Lemus, Juan   Tharp, Emily   Olson, Scott   Triolo, Fabio   Bianchi, Joana   Ritter III, Robert   Schiess, Mya   

Session Name:P8: Movement Disorders: Parkinson's Disease Emerging Therapeutics 2  

Topic:Movement Disorders  

Program Number:P8.011  

Author Institution:University of Texas Health Sciences Center at Houston, TX  University of Texas Health Sciences Center at Houston, Houston, TX  

Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of ACP-711 (SAN711): A Novel GABAA Subunit a3 Selective Modulator

Author:Amrutkar, Dipak V.   Sandager-Nielsen, Karin   Dyhring, Tino   Jacobsen, Thomas Amos   Larsen, Janus S.   Muglia, Pierandrea   Pathak, Sanjeev   Lin, Hank   Hofbauer, Robert   

Session Name:P8: Movement Disorders: Parkinson's Disease Emerging Therapeutics 2  

Topic:Movement Disorders  

Program Number:P8.012  

Author Institution:Saniona A/S, Glostrup, Denmark  Acadia Pharmaceuticals, Inc., Princeton, NJ  Acadia Pharmaceuticals, Inc., San Diego, CA  

Impact of ND0612 on Levodopa-induced Dyskinesia in Parkinson’s Disease: Post-hoc Analyses from a Randomized, Active-controlled Study

Author:Ellenbogen, Aaron   Pahwa, Rajesh   hernandez-vara, jorge   Lopes, Nelson   Salah, Alejandro   Espay, Alberto   

Session Name:P8: Movement Disorders: Parkinson's Disease Emerging Therapeutics 2  

Topic:Movement Disorders  

Program Number:P8.013  

Author Institution:Quest Research Institute, Farmington Hills, MI  University of Kansas Medical Center, Kansas City, KS  Vall D,Hebron Hospital, Barcelona, Spain  NeuroDerm Ltd, Israel  Mitsubishi Tanabe Pharma America, New York, NY  James J. and Joan A. Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH